Summary of Key Points Core Viewpoint - 医渡科技 has been actively repurchasing its shares, indicating confidence in its market position and future prospects [1] Group 1: Share Buyback Activity - On October 17, 医渡科技 spent HKD 1.013 million to repurchase 181,000 shares [1] - This week, the company has conducted three buybacks totaling approximately 2.685 million shares, with a total expenditure exceeding HKD 15.6 million [1] - Since September 26, the company has executed five buybacks, amounting to around 3.373 million shares and nearly HKD 20 million in total [1] Group 2: Southbound Capital Inflows - On October 14, southbound funds net purchased HKD 34.7273 million worth of 医渡科技 shares, marking the highest net inflow since September 1, 2025 [1] - The net buying has continued for three consecutive days, with a cumulative net purchase of HKD 57.79 million [1] Group 3: Product Development and Market Support - Recently, the world's first topical treatment for proliferative superficial infantile hemangioma, Timolol Maleate Gel, has been approved for market release [1] - 医渡科技 provided critical market research and project analysis services that supported the drug's development and market entry [1]

Core Viewpoint - 医渡科技 announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company plans to repurchase 181,200 shares at a total cost of HKD 1.0131 million [1] - The buyback price per share ranges from HKD 5.56 to HKD 5.65 [1] - The buyback is scheduled for October 17, 2025, reflecting a strategic move to enhance shareholder value [1]

智通财经APP讯，医渡科技(02158)发布公告，于2025年10月17日，该公司斥资101.31万港元回购18.12万 股股份，每股回购价格为5.56-5.65港元。 ...

Core Viewpoint - The company, Yidu Tech (02158.HK), announced a share buyback on October 17, 2023, spending HKD 1.013 million to repurchase 181,000 shares at a price range of HKD 5.56 to 5.65 per share [1] Summary by Category - **Company Actions** - Yidu Tech executed a buyback of 181,000 shares at a total cost of HKD 1.013 million [1] - The repurchase price per share ranged from HKD 5.56 to 5.65 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年10月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 第一章節註釋： | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股 ...

Core Insights - The core viewpoint of the news is that Yidu Technology, a leading player in China's AI healthcare industry, has made significant progress across various business segments, including clinical research services, hospital AI construction, innovative drug development support, and health insurance operations, showcasing a strong trend of collaborative development among its diverse business lines. Group 1: Clinical Research Services - Yidu Technology successfully won the bid for the phase III clinical research project of recombinant human nerve growth factor (SMR001) eye drops for Shandong Yandu Biotechnology Co., with a total project amount of approximately RMB 55.82 million [2] - The company also secured a project for AI construction at Beijing Cancer Hospital, amounting to RMB 4.88 million, marking the first large model application project at a hospital level, setting a precedent for future large model business expansion [2] Group 2: Innovative Drug Development - In the innovative drug development support sector, the first innovative drug DF-006 developed by Drug Ranch has received approval from the China National Medical Products Administration to conduct phase 1b clinical trials in patients with chronic hepatitis B [3] - Yidu Technology played a crucial role as a service support provider for this project, leveraging its regulatory expertise and efficient project execution to facilitate the successful approval of the clinical trial application [3] Group 3: Health Insurance Operations - As the main operating platform for "Beijing Inclusive Health Insurance," Yidu Technology actively supported the 2025 Financial Education Promotion Week [4] - By the end of August 2025, the "Beijing Inclusive Health Insurance" had processed a total of 419,000 claims, with the highest single claim amount reaching RMB 761,100, and 89% of claims being processed quickly, effectively providing medical coverage for residents of Beijing [4] - The solid advancement of various business segments reflects Yidu Technology's professional capabilities and innovative vitality in the medical AI field, accelerating the synergy of its diverse business operations and laying a solid foundation for future development [4]

Core Viewpoint - The company, Yidu Technology (02158.HK), has been actively repurchasing its shares, indicating a strategy to support its stock price amid recent declines [2][3]. Summary by Sections Share Buyback Activity - On October 14, Yidu Technology repurchased 1.4728 million shares at prices ranging from 5.750 to 5.990 HKD, totaling 8.5796 million HKD [2]. - The stock closed at 5.760 HKD on the same day, reflecting a decrease of 4.00%, with a total trading volume of 97.4232 million HKD [2]. - Since October 13, the company has conducted buybacks for two consecutive days, acquiring a total of 2.5036 million shares for a cumulative amount of 14.6717 million HKD, during which the stock price fell by 6.49% [2]. Year-to-Date Buyback Summary - Year-to-date, Yidu Technology has executed four buyback transactions, acquiring a total of 3.1916 million shares for a total expenditure of 18.5980 million HKD [3]. - The detailed buyback transactions are as follows: - October 14: 1.4728 million shares at a maximum price of 5.990 HKD and a minimum price of 5.750 HKD, totaling 8.5796 million HKD [3]. - October 13: 1.0308 million shares at a maximum price of 5.990 HKD and a minimum price of 5.800 HKD, totaling 6.0920 million HKD [3]. - September 29: 0.3350 million shares at a maximum price of 5.790 HKD and a minimum price of 5.670 HKD, totaling 1.9271 million HKD [3]. - September 26: 0.3530 million shares at a maximum price of 5.690 HKD and a minimum price of 5.570 HKD, totaling 1.9992 million HKD [3].

该信息由智通财经网提供 智通财经APP讯，医渡科技(02158)发布公告，该公司于2025年10月14日斥资857.96万港元回购147.28万 股股份，每股回购价格为5.75-5.99港元。 ...

Core Viewpoint - The company, Yidu Technology (02158), has been actively repurchasing its shares, indicating confidence in its stock value and financial health. Additionally, the approval of a new drug for infant vascular tumors highlights the company's role in supporting pharmaceutical development through market research and analysis services [1]. Share Buyback Activity - On October 14, Yidu Technology repurchased 1.4728 million shares at a price range of HKD 5.75 to HKD 5.99 per share, totaling HKD 8.58 million [1]. - Since September 26, the company has conducted four share buybacks, accumulating a total of 3.1916 million shares repurchased, with a total expenditure of HKD 18.6359 million [1]. Drug Approval and Market Support - The company provided critical market research and project analysis services for the recently approved topical treatment, Timolol Maleate Gel, which is the first drug targeting proliferative superficial infantile hemangiomas [1].

Core Viewpoint - Medicure Technology (02158) has been actively repurchasing its shares, indicating confidence in its stock value and future prospects [1] Share Buyback Activity - On October 14, Medicure Technology repurchased 1.4728 million shares at a price range of HKD 5.75 to HKD 5.99, totaling HKD 8.58 million [1] - Since September 26, the company has conducted four share buybacks, accumulating a total of 3.1916 million shares repurchased, with a total expenditure of HKD 18.6359 million [1] Product Development and Market Support - The company has provided critical market research and project analysis services for the recently approved topical treatment for infantile hemangiomas, marking a significant advancement in its product offerings [1]